Literature DB >> 1593054

Comparison of the cost of radiofrequency catheter modification of the atrioventricular node and medical therapy for drug-refractory atrioventricular node reentrant tachycardia.

S J Kalbfleisch1, H Calkins, J J Langberg, R el-Atassi, A Leon, M Borganelli, F Morady.   

Abstract

The purpose of this study was to determine the charges for radiofrequency catheter modification of the atrioventricular (AV) node in 15 patients with symptomatic AV node reentrant tachycardia despite pharmacologic therapy and to compare these charges with the estimated charges for health care utilization by the same patients before the catheter procedure was performed. There were seven men and eight women with a mean age of 50 +/- 17 years. The mean duration and frequency of symptoms were 16 +/- 9 years and 4.5 +/- 6 episodes/month, respectively. Fourteen of the 15 patients required only one procedure for diagnosis and cure of AV node reentrant tachycardia and 1 patient required two sessions. All patients underwent electrophysiologic study before discharge from the hospital to confirm the short-term efficacy of the procedure. The mean duration of the hospital stay was 3 +/- 1.5 days and the mean total charge/patient expressed in 1991 dollars was $15,893 +/- $3,338 for catheter modification. These total charges consisted of hospital charges of $8,105 +/- $2,466 and physician charges of $7,788 +/- $971. All patients had a successful outcome and required no additional antiarrhythmic therapy. The estimated cost of health care utilization for these 15 patients before cure of AV node reentrant tachycardia was $7,651/patient per year. These estimated costs included charges incurred for emergency room visits, office visits, hospitalizations and antiarrhythmic drug therapy. In conclusion, the results of this study indicate that the annual health care costs incurred by patients who have symptomatic, drug-refractory paroxysmal supraventricular tachycardia caused by AV node reentry are substantial.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1593054     DOI: 10.1016/0735-1097(92)90621-s

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Supraventricular Tachyarrhythmia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-08

2.  Pharmacoeconomic considerations in antiarrhythmic therapy.

Authors:  P J Podrid; R J Arnold; D J Kaniecki
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

Review 3.  Advances in cardiology: the complementary roles of concept and technology.

Authors:  R Gorlin
Journal:  J Interv Card Electrophysiol       Date:  1997-12       Impact factor: 1.900

4.  Radiofrequency catheter ablation of supraventricular tachycardia in children and adolescents : feasibility and cost-effectiveness in a low-income country.

Authors:  Vladimiro L Vida; Gonzalo S Calvimontes; Maximo O Macs; Patricia Aparicio; Joaquin Barnoya; Aldo R Castañeda
Journal:  Pediatr Cardiol       Date:  2006-07-06       Impact factor: 1.655

5.  Outpatient radiofrequency catheter ablation.

Authors:  F Bogun; F Morady
Journal:  Herz       Date:  1998-02       Impact factor: 1.443

6.  Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala: Patient outcomes and economic analysis from a low-middle-income country.

Authors:  Benjamin Cruz Rodriguez; Sergio Leal; Gonzalo Calvimontes; David Hutton
Journal:  Value Health Reg Issues       Date:  2015-09-25

7.  Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias (COBRA-PATH): a randomized controlled trial.

Authors:  Tamas Geczy; Nawin L Ramdat Misier; Tamas Szili-Torok
Journal:  Trials       Date:  2020-04-09       Impact factor: 2.279

8.  Atrioventricular nodal reentrant tachycardia in a nonagenarian-Triple traps of AV block.

Authors:  Yuichiro Miyazaki; Takashi Noda; Koji Miyamoto; Satoshi Nagase; Takeshi Aiba; Kengo Kusano
Journal:  HeartRhythm Case Rep       Date:  2021-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.